<qa>  What is the rate of toxicity experienced in the triple combination regimen?Phase II: Confidence intervals for the difference in the incidence of bevacizumab and MMC associated grade 34 toxicities on the three arms will be calculated. If the incidence of these toxicities in the triple combination regimen CapecitabineMMC bevacizumab exceeds the rate of toxicity experienced in the capecitabinebevacizumab combination by more than 20 then consideration will be given to dose adjustment or stopping recruitment into the triple combination arm. 